

# ForPatients

by Roche

Triple Negative Breast Cancer Ovarian Cancer

## A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

**Trial Status**  
Completed

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT03101280 2016-002610-47  
WO39409

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a Phase Ib, open-label, non-randomized study in patients with previously treated advanced ovarian or endometrial cancer (Part 1) and platinum-sensitive ovarian cancer or triple-negative breast cancer (TNBC) (Part 2) to investigate the dose, safety, pharmacokinetics, and preliminary efficacy of rucaparib in combination with atezolizumab. The study is conducted in 2 parts: a Dose-Finding Phase (Part 1) and a Dose-Expansion Phase (Part 2)

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03101280 2016-002610-47 WO39409**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
Female

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---